Self-encapsulating Poly(lactic-<i>co</i>-glycolic acid) (PLGA) Microspheres for Intranasal Vaccine Delivery

Bailey, Brittany A.; Desai, Kashappa Goud H.; Ochyl, Lukasz J.; Ciotti, Susan; Moon, James J.; Schwendeman, Steven P.

doi:10.1021/acs.molpharmaceut.7b00586

Cited by 28 publications

(15 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2017, Green and co‐workers studied the combination of PLGA aAPCs in combination with an anti‐PD‐1 checkpoint blockade against murine melanoma . Later that year, Schwendeman and Moon developed self‐healing PLGA microspheres with calcium phosphate (CaHPO 4 ) adjuvant gel to enhance antigen protection for improved T cell induction . Taken together, these studies provide a roadmap for the design of biodegradable aAPCs.…”

Section: Microscale Materials For Immunotherapymentioning

confidence: 99%

Materials for Immunotherapy

et al. 2019

View full text Add to dashboard Cite

Breakthroughs in materials engineering have accelerated the progress of immunotherapy in preclinical studies. The interplay of chemistry and materials has resulted in improved loading, targeting, and release of immunomodulatory agents. An overview of the materials that are used to enable or improve the success of immunotherapies in preclinical studies is presented, from immunosuppressive to proinflammatory strategies, with particular emphasis on technologies poised for clinical translation. The materials are organized based on their characteristic length scale, whereby the enabling feature of each technology is organized by the structure of that material. For example, the mechanisms by which i) nanoscale materials can improve targeting and infiltration of immunomodulatory payloads into tissues and cells, ii) microscale materials can facilitate cell‐mediated transport and serve as artificial antigen‐presenting cells, and iii) macroscale materials can form the basis of artificial microenvironments to promote cell infiltration and reprogramming are discussed. As a step toward establishing a set of design rules for future immunotherapies, materials that intrinsically activate or suppress the immune system are reviewed. Finally, a brief outlook on the trajectory of these systems and how they may be improved to address unsolved challenges in cancer, infectious diseases, and autoimmunity is presented.

show abstract

Section: Microscale Materials For Immunotherapymentioning

confidence: 99%

Materials for Immunotherapy

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Four styles of patches were evaluated: (a) a non‐dissolving MNP of equivalent geometry that was made of high Mw poly(lactic acid) (PLA) (fabricated as previously reported) and did not deposit material in the skin, (b) the microparticle‐loaded dissolving pedestal MNPs explored above, (c) dissolving pedestal MNPs that contained nanoparticles rather than microparticles (median diameter = 7.1 μm), and (d) a dissolving pedestal MNP that did not contain any microparticles (vehicle).…”

Section: Resultsmentioning

confidence: 99%

“…TEWL was measured using a Delfin Technologies VapoMeter with DelfWin 4 capture software. Study groups consisted of application of: (a) PLA master patches (no pedestal), (b) ASE microparticle‐loaded pedestal patches, (c) pedestal patches loaded with smaller nano‐sized PLGA particles, and (d) vehicle‐only patches (pedestal MNPs made of only PVA/sucrose, no microparticles). Three measurements were taken per application site, per animal, at each timepoint, and the TEWL chamber was allowed to re‐equilibrate to environmental conditions before each measurement.…”

Section: Methodsmentioning

confidence: 99%

Self‐healing encapsulation and controlled release of vaccine antigens from PLGA microparticles delivered by microneedle patches

Mazzara

Ochyl

Hong

et al. 2018

Bioengineering & Transla Med

Self Cite

View full text Add to dashboard Cite

There is an urgent need to reduce reliance on hypodermic injections for many vaccines to increase vaccination safety and coverage. Alternative approaches include controlled release formulations, which reduce dosing frequencies, and utilizing alternative delivery devices such as microneedle patches (MNPs). This work explores development of controlled release microparticles made of poly (lactic‐co‐glycolic acid) (PLGA) that stably encapsulate various antigens though aqueous active self‐healing encapsulation (ASE). These microparticles are incorporated into rapid‐dissolving MNPs for intradermal vaccination.PLGA microparticles containing Alhydrogel are loaded with antigens separate from microparticle fabrication using ASE. This avoids antigen expsoure to many stressors. The microparticles demonstrate bi‐phasic release, with initial burst of soluble antigen, followed by delayed release of Alhydrogel‐complexed antigen over approximately 2 months in vitro. For delivery, the microparticles are incorporated into MNPs designed with pedestals to extend functional microneedle length. These microneedles readily penetrate skin and rapidly dissolve to deposit microparticles intradermally. Microparticles remain in the tissue for extended residence, with MNP‐induced micropores resealing readily. In animal models, these patches generate robust immune responses that are comparable to conventional administration techniques. This lays the framework for a versatile vaccine delivery system that could be self‐applied with important logistical advantages over hypodermic injections.

show abstract

“…Polymeric particles are the main focus for development of a single-dose delayed-release vaccine that could replace the need for booster doses of many current vaccines [81]. The antigen release profile of a PLGA particle can be modified from a couple of days to more than a year [82,83]. Many studies have also used polymeric particles for their ability to act as an adjuvant, rather than their antigen release profile.…”

Section: Polymeric Particlesmentioning

confidence: 99%

Novel approaches for the design, delivery and administration of vaccine technologies

Wallis

Shenton

Carlisle

2019

Clinical and Experimental Immunology

100

View full text Add to dashboard Cite

Summary It is easy to argue that vaccine development represents humankind’s most important and successful endeavour, such is the impact that vaccination has had on human morbidity and mortality over the last 200 years. During this time the original method of Jenner and Pasteur, i.e. that of injecting live‐attenuated or inactivated pathogens, has been developed and supplemented with a wide range of alternative approaches which are now in clinical use or under development. These next‐generation technologies have been designed to produce a vaccine that has the effectiveness of the original live‐attenuated and inactivated vaccines, but without the associated risks and limitations. Indeed, the method of development has undoubtedly moved away from Pasteur’s three Is paradigm (isolate, inactivate, inject) towards an approach of rational design, made possible by improved knowledge of the pathogen–host interaction and the mechanisms of the immune system. These novel vaccines have explored methods for targeted delivery of antigenic material, as well as for the control of release profiles, so that dosing regimens can be matched to the time‐lines of immune system stimulation and the realities of health‐care delivery in dispersed populations. The methods by which vaccines are administered are also the subject of intense research in the hope that needle and syringe dosing, with all its associated issues regarding risk of injury, cross‐infection and patient compliance, can be replaced. This review provides a detailed overview of new vaccine vectors as well as information pertaining to the novel delivery platforms under development.

show abstract

Self-encapsulating Poly(lactic-co-glycolic acid) (PLGA) Microspheres for Intranasal Vaccine Delivery

Cited by 28 publications

References 41 publications

Materials for Immunotherapy

Materials for Immunotherapy

Self‐healing encapsulation and controlled release of vaccine antigens from PLGA microparticles delivered by microneedle patches

Novel approaches for the design, delivery and administration of vaccine technologies

Contact Info

Product

Resources

About